Minoxidil
Also known as: Rogaine, Regaine, Loniten, LDOM, Oral Minoxidil, Minox
Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Minoxidil is a vasodilator, an ATP-sensitive potassium-channel opener originally approved as an oral antihypertensive, whose hair growth was discovered as a side effect. It has no androgenic, anabolic or ergogenic action: it does not bind the androgen receptor, does not affect the HPT axis, and does not build muscle. It is a purely cosmetic hair drug used to offset the hair loss a cycle accelerates, so it does not move the natural ceiling by any path. Rated 1 (basically natty), same as finasteride.
Overview
A potassium-channel-opening vasodilator that is the only non-hormonal drug with FDA approval for androgenetic alopecia. It grows hair by pushing follicles out of the resting phase and extending the growth phase. It does NOT block DHT, so it treats the symptom rather than the cause. That makes it the one hair drug that works regardless of which compound is driving the loss, including the DHT-derivatives and 19-nors that finasteride cannot help with.
Important Warnings
- •Oral minoxidil for hair loss is OFF-LABEL. Its only approved oral indication is resistant hypertension
- •Do not confuse hair-loss dosing (roughly 0.625-5mg/day) with antihypertensive dosing (up to 100mg/day)
- •Oral minoxidil can cause pericardial effusion, pericarditis and cardiac tamponade. Rare but serious
- •Expect an initial shed in the first weeks; it is mechanistic, not treatment failure
- •Hair gains are lost after discontinuation. This is a permanent commitment, not a course
- •Low-dose aspirin inhibits sulfotransferase and can diminish topical minoxidil effectiveness
- •Contraindicated in pregnancy (Category C) and breastfeeding; not labeled for under-18s
- •Additive hypotension risk when combined with other blood-pressure medication
- •Hypertrichosis (unwanted facial/body hair) is dose-dependent and common
Purpose & Use Cases
Hair Loss Treatment That Works On Any Compound
Because it is non-hormonal, minoxidil does not care what is driving the miniaturization. It is the only hair option that still applies on DHT-derivatives (Masteron, Winstrol, Anavar, Proviron) and 19-nors, where finasteride is respectively useless and counterproductive.
Pairing With A 5-AR Inhibitor
Minoxidil grows hair; finasteride/dutasteride stop the DHT that is killing it. The two attack different halves of the problem, which is why they are routinely run together rather than as alternatives.
Resistant Hypertension (Its Actual Approved Indication)
Oral minoxidil is FDA-approved only for hypertension uncontrolled by three antihypertensive drug classes at maximum doses, where it must be combined with a beta-blocker and a loop diuretic to control reflex tachycardia and fluid retention.
Benefits
- The only FDA-approved non-hormonal treatment for androgenetic alopecia
- Works independently of DHT. Effective alongside DHT-derivatives and 19-nors where finasteride is not
- No effect on the HPT axis, no suppression, no PCT implications
- 5% topical provides more clinical benefit than 2% (per FDA labeling and StatPearls)
- Only ~1.4% of topical minoxidil is absorbed through the skin, keeping systemic exposure minimal
- Oral route avoids the daily application, scalp irritation and propylene-glycol dermatitis of the topical
- Cheap and widely available as a generic
Good to Know
It does not block DHT, that is the point
Finasteride and dutasteride attack the cause (DHT). Minoxidil attacks the symptom (miniaturized follicles) by forcing them back into the growth phase. Neither replaces the other, which is why they are run together. It also means minoxidil is the only option that still works when the offending compound is a DHT-derivative or a 19-nor.
The sulfotransferase lottery
Minoxidil is a prodrug that scalp sulfotransferase enzymes must convert into minoxidil sulfate before it does anything. How much of that enzyme you have is largely genetic, and it is the main reason response varies so much between users. Some people are simply poor converters. The oral route sidesteps some, but not all, of this variability.
Low-dose aspirin can blunt topical minoxidil
StatPearls documents that low-dose aspirin inhibits sulfotransferase and can diminish the effectiveness of topical minoxidil. If you run a daily aspirin as part of a fat-burner or cardiovascular protocol, that is a real interaction with your hair protocol.
The initial shed is supposed to happen
Minoxidil shortens telogen, so a batch of resting hairs is released at once when you start. It looks like the drug is making things worse in weeks 2-8. Stopping resets the clock. Initial results appear around 8 weeks, with maximum effect near 4 months.
Oral and topical are not the same risk profile
Topical is ~1.4% absorbed and essentially a local drug. Oral minoxidil is a systemic antihypertensive whose approved dose goes up to 100mg/day for resistant hypertension. Hair-loss dosing is a small fraction of that (roughly 0.625-5mg/day per the 2025 JAMA Dermatology consensus), but the cardiovascular effects are dose-dependent and real.
Stopping means losing what you gained
Minoxidil maintains hair only while it is being used. The gains are not permanent. The drug is a continuous requirement, not a course, which is why cycle length here is measured in years rather than weeks.
Dosage Guidelines
| Route | Typical Dose | Frequency | Cycle |
|---|---|---|---|
| Oral | 1.25 – 2.5 mg/day | Once daily (StatPearls describes off-label hair-loss dosing as 0.25-2.5mg once or twice daily) | 24 – 52 wk |
| Topical solution / foam (FDA-approved) | 2 – 2 mL/day | Twice daily | 24 – 52 wk |
Dosing depends on how it's administered. Pick your route in the calculator to score the one you use.
These are LOW-DOSE ORAL MINOXIDIL (LDOM) figures for hair loss, which is an off-label use, not the antihypertensive dose. The 2025 JAMA Dermatology international modified Delphi consensus (43 hair-loss specialist dermatologists across 12 countries) reached agreement on off-label LDOM in the range of 0.625-5mg daily, with current practice initiating low (typically 0.5-1.25mg) and titrating to response and tolerance. StatPearls gives the off-label hair-loss range as 0.25-2.5mg once or twice daily. For comparison, the approved ANTIHYPERTENSIVE dose is an entirely different magnitude: 5mg once daily to start, 0.25-1mg/kg daily maintenance, up to a maximum of 100mg/day. Do not confuse the two. Results take ~8 weeks to appear and peak around 4 months.
Per StatPearls, the labeled schedule for men is 1mL of 2% or 5% solution applied to the scalp twice daily, so 2mL/day total. Women are labeled for 1mL of the 2% solution twice daily, or one-half capful of the 5% foam twice daily. 5% delivers more clinical benefit than 2%. Uptake reaches roughly 50% within an hour and 75% after 4 hours, so allow at least an hour before showering. Only ~1.4% is absorbed systemically.
Plasma half-life is 3-4 hours, but the pharmacodynamic effect long outlasts it. StatPearls notes the hypotensive effect can persist up to 72 hours. Hair effects are on a completely different timescale: initial results appear at roughly 8 weeks with maximum effect around 4 months.
Side Effects
Hypertrichosis (unwanted body/facial hair)
commonHair growth where you did not want it, face, arms, back. StatPearls lists localized or generalized hypertrichosis as more common with the 5% topical formulation, and as a recognised effect of oral minoxidil. It is dose-dependent.
Reduce the dose. Resolves after discontinuation. Ciclosporin co-administration exacerbates it.
Telogen effluvium (initial shedding)
commonA wave of shedding in the first weeks. It is mechanistic, not a failure, minoxidil shortens the telogen phase, so resting hairs are released together as follicles are pushed into anagen.
Expected and self-limiting. Push through it rather than stopping, or the cycle restarts.
Fluid retention / peripheral edema
uncommonSalt and water retention is an intrinsic consequence of the vasodilation, listed by StatPearls among oral minoxidil effects alongside tachycardia and weight gain.
Dose-dependent. In its antihypertensive use it is specifically co-prescribed with a loop diuretic and a beta-blocker for this reason. Report persistent swelling or rapid weight gain.
Tachycardia
uncommonReflex increase in heart rate from peripheral vasodilation, a systemic (oral) effect rather than a topical one.
Dose-dependent. Relevant to stack with stimulants or on-cycle blood pressure elevation.
Pericardial effusion / pericarditis / tamponade
rareStatPearls lists pericarditis, pericardial effusion and cardiac tamponade among oral minoxidil adverse effects. These are the serious cardiac complications that drive the monitoring requirements for the drug.
Seek medical attention for chest pain or shortness of breath. StatPearls recommends monitoring including echocardiogram, renal function, fundoscopic exam and ankle-brachial index for oral users.
Scalp irritation / allergic contact dermatitis
commonItching, redness and flaking with the topical. Propylene glycol in the solution is the primary allergen, foam formulations generally omit it.
Switch to a foam formulation or move to the oral route.
Breast tenderness / gynecomastia
rareStatPearls lists breast tenderness and gynecomastia among oral minoxidil adverse effects.
Discontinue or reduce dose if it develops.
Hypotension, thrombocytopenia, leukopenia
rareStatPearls notes significant hypotension and potential complications such as thrombocytopenia and leukopenia with oral minoxidil.
Relevant mainly at antihypertensive doses. Do not self-escalate toward those doses.
General Mitigation Strategies
Topical minoxidil is a low-risk drug, only ~1.4% is absorbed, so the meaningful complaints are local (irritation, contact dermatitis from propylene glycol, hypertrichosis at the application site) plus the expected initial shed. Oral minoxidil is a genuine systemic cardiovascular drug and deserves more respect: the effects that matter are fluid retention, tachycardia and, rarely, pericardial effusion. Start at the bottom of the LDOM range and titrate. Anyone already running compounds that elevate blood pressure and hematocrit should factor that in before adding a systemic vasodilator. Note the drug interactions StatPearls documents: ciclosporin worsens hypertrichosis, guanethidine risks severe hypotension, and low-dose aspirin inhibits sulfotransferase and can therefore diminish topical minoxidil effectiveness.
Support Supplements
Ancillary supplements commonly run alongside Minoxidil to manage side effects, support the target tissue, or fill nutrient demands it creates.
Finasteride or dutasteride
Removes the DHT driving the loss: minoxidil alone treats the symptom, not the cause
- Dose
- Finasteride 1mg/day or dutasteride 0.5mg/day
- When
- Only useful when the hair loss is DHT-driven and the cycle is testosterone-based; useless on DHT-derivatives
Ketoconazole 2% shampoo
Adjunct with independent evidence in androgenetic alopecia; addresses scalp inflammation
- Dose
- 2-4x weekly
Blood pressure monitoring
KeyOral minoxidil is an antihypertensive with dose-dependent tachycardia and fluid retention
- Timing
- Baseline and periodically after any dose increase
- When
- Specific to the oral route: the topical is systemically negligible
Post Cycle Therapy (PCT)
No HPT axis interaction at all. No PCT implications. Can be run continuously, and generally must be. The effect ends when the drug does.
How It Works
Minoxidil is a prodrug. Sulfotransferase enzymes in the scalp convert it to minoxidil sulfate, the active form, and individual variation in that enzyme activity is the main reason response rates vary so widely between users. The active drug shortens the telogen (resting) phase and pushes follicles into anagen (growth), extends the anagen phase to increase hair length and thickness, opens ATP-sensitive potassium channels to produce arteriolar vasodilation and improve follicular microcirculation, increases vascular endothelial growth factor expression, and activates prostaglandin-endoperoxide synthase-1. Its antihypertensive action is the same potassium-channel mechanism acting on vascular smooth muscle, which is why systemic dosing causes reflex tachycardia and salt/water retention.
Hormonal & Androgenic Profile
N/A: not an androgen and does not bind the androgen receptor.
Not a hormonal drug: no aromatase or estrogen relevance whatsoever.
None: and that is precisely why it matters here. Minoxidil does not touch 5-alpha-reductase or DHT; it stimulates the follicle downstream of whatever is attacking it. That makes it the only hair drug that still works on DHT-derivatives (Masteron, Winstrol, Anavar, Proviron, Primobolan), where finasteride has nothing to block, and on 19-nors, where finasteride actively makes things worse.
The topical route is systemically negligible (~1.4% absorbed). The oral route is a real antihypertensive: it lowers blood pressure by vasodilation and causes compensatory tachycardia and salt/water retention, with rare pericardial effusion. Worth weighing against the blood pressure and hematocrit elevation an AAS cycle already causes.
Fundamentals
Reference on the practices relevant to Minoxidil: how they are done and where they go wrong. Not a recommendation to use it.
Common Stacks
- Minoxidil + Finasteride: the standard two-drug hair protocol, non-overlapping mechanisms
- Minoxidil + Finasteride + Ketoconazole shampoo: the common "big three"
- Minoxidil alone: the correct choice on DHT-derivatives (Masteron, Winstrol, Anavar, Proviron) where 5-AR inhibitors do nothing
- Minoxidil over finasteride on 19-nors (Deca/NPP), where finasteride can worsen hair loss
Legal Status
Topical minoxidil (2% and 5% solution and foam) is FDA-approved OTC for androgenetic alopecia in patients 18 and over. Oral minoxidil is a prescription drug approved only for resistant hypertension. Its use for hair loss is off-label. Not a controlled substance.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Minoxidil is a vasodilator, not a diuretic or masking agent, and is not listed on the WADA Prohibited List. It has no performance-enhancing action.
References
- StatPearls: Minoxidil (mechanism, dosing, PK, adverse effects, monitoring)
- JAMA Dermatology 2025: Low-Dose Oral Minoxidil Initiation for Patients With Hair Loss: An International Modified Delphi Consensus Statement
- Frontiers in Pharmacology: Expanding the therapeutic landscape of minoxidil for androgenetic alopecia: topical, oral and sublingual formulations
- PubMed: Sulfotransferase activity in plucked hair follicles predicts response to topical minoxidil